The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Cabotegravir · Kit · ViiV Healthcare Company
NDC 49702-0280-63 · 1 KIT in 1 CARTON * 3 mL in 1 VIAL · NDA · View full market →
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Not scored — fragility is computed for NADAC-priced NDCs.
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NCE | Jan 21, 2026 |
| patent | 12138264 | Sep 15, 2031 |
| patent | 11224597 | Sep 15, 2031 |
| patent | 8410103 | Feb 4, 2031 |
| patent | 10927129 | Apr 28, 2026 |
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| ViiV Healthcare Company | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Apretude — NDC 49702-0280-63," retrieved September 3, 2026, https://drugdashboards.com/drug/49702028063.
Free to cite with attribution — see how the data is put together.